Format
Items per page
Sort by

Send to:

Choose Destination

Links from Books

Items: 1 to 20 of 24

1.

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Yang Y, Lewis JP, Hulot JS, Scott SA.

Expert Opin Drug Metab Toxicol. 2015;11(10):1599-617. doi: 10.1517/17425255.2015.1068757. Epub 2015 Jul 14.

PMID:
26173871
2.

Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?

Reny JL, Fontana P.

Expert Opin Pharmacother. 2015 Mar;16(4):449-52. doi: 10.1517/14656566.2015.993608. Epub 2014 Dec 11.

PMID:
25495963
3.

Genetics of platelet inhibitor treatment.

Trenk D, Hochholzer W.

Br J Clin Pharmacol. 2014 Apr;77(4):642-53. doi: 10.1111/bcp.12230. Review.

4.

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.

5.

Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.

Reny JL, Combescure C, Daali Y, Fontana P; PON1 Meta-Analysis Group.

J Thromb Haemost. 2012 Jul;10(7):1242-51. doi: 10.1111/j.1538-7836.2012.04756.x. Review.

6.

Prevalence of poor biological response to clopidogrel: a systematic review.

Mallouk N, Labruyère C, Reny JL, Chapelle C, Piot M, Fontana P, Gris JC, Delavenne X, Mismetti P, Laporte S.

Thromb Haemost. 2012 Mar;107(3):494-506. doi: 10.1160/TH11-03-0202. Epub 2012 Jan 25. Review.

PMID:
22273694
7.

Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.

Lewis JP, Fisch AS, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Shen H, Tanner K, Horenstein RB, Pakzy R, Tantry US, Bliden KP, Gurbel PA, Shuldiner AR.

Clin Pharmacol Ther. 2011 Oct;90(4):568-74. doi: 10.1038/clpt.2011.194. Epub 2011 Aug 31. Erratum in: Clin Pharmacol Ther. 2012 Apr;91(4):751.

8.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

9.

Pharmacogenetics: from bench to byte--an update of guidelines.

Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ.

Clin Pharmacol Ther. 2011 May;89(5):662-73. doi: 10.1038/clpt.2011.34. Epub 2011 Mar 16. Review.

PMID:
21412232
10.

Paraoxonase-1 is a major determinant of clopidogrel efficacy.

Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D.

Nat Med. 2011 Jan;17(1):110-6. doi: 10.1038/nm.2281. Epub 2010 Dec 19. Erratum in: Nat Med. 2011 Sep;17(9):1153.

PMID:
21170047
11.

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS.

JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.

12.

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A.

Drug Metab Dispos. 2010 Jan;38(1):92-9. doi: 10.1124/dmd.109.029132. Epub .

13.

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA.

JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.

14.

Cytochrome p-450 polymorphisms and response to clopidogrel.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS.

N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22.

15.

Genetic determinants of response to clopidogrel and cardiovascular events.

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators.

N Engl J Med. 2009 Jan 22;360(4):363-75. doi: 10.1056/NEJMoa0808227. Epub 2008 Dec 22.

16.

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.

Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, Zuern C, Moerike K, Gawaz M, Schwab M.

Pharmacogenomics. 2008 Sep;9(9):1251-9. doi: 10.2217/14622416.9.9.1251.

17.

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE.

Clin Pharmacol Ther. 2007 May;81(5):735-41. Epub 2007 Mar 14.

PMID:
17361128
18.

Impact of P-glycoprotein on clopidogrel absorption.

Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E.

Clin Pharmacol Ther. 2006 Nov;80(5):486-501.

PMID:
17112805
19.

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P.

Blood. 2006 Oct 1;108(7):2244-7. Epub 2006 Jun 13.

20.

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.

Lancet. 2005 Nov 5;366(9497):1607-21.

PMID:
16271642
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk